• EMBARC: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care
Establishing Moderators and Biosignatures of
Antidepressant Response for Clinical Care

Have you been feeling down, depressed, or hopeless?
Having trouble sleeping or concentrating?

You may be eligible to participate in a study at Massachusetts General Hospital. This study is examining several clinical and biological measures related to depression to see whether they can tell us in advance which antidepressant might work best and cause the fewest side effects for someone with depression.

In this study, you will be randomized to receive sertraline (Zoloft™), bubropion XL (Wellbutrin XL™) or placebo over the course of 18 weeks. Additionally, you will be asked to complete three Magnetic Resonance Imaging (MRI) as well as three Electroencephalography (EEG) scans. If all parts of the study are completed, you will be compensated up to $725 for your time and effort. At the end of the study, you will be offered three months of follow-up care at no cost.

If you are between 18 and 65 years old and would like more information, please contact Angela at 617-726-0517. All inquiries will be kept completely confidential.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – Maurizio Fava, MD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Pisoni Angela
Email  – apisoni@partners.org
Phone  – 617-726-0517